ondansetron has been researched along with Headache in 25 studies
Ondansetron: A competitive serotonin type 3 receptor antagonist. It is effective in the treatment of nausea and vomiting caused by cytotoxic chemotherapy drugs, including cisplatin, and has reported anxiolytic and neuroleptic properties.
Headache: The symptom of PAIN in the cranial region. It may be an isolated benign occurrence or manifestation of a wide variety of HEADACHE DISORDERS.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The purpose of this phase III trial was to evaluate the efficacy and safety of regimens containing casopitant, a novel neurokinin-1 receptor antagonist, for the prevention of chemotherapy-induced nausea and vomiting during the first cycle in patients receiving moderately emetogenic chemotherapy (MEC)." | 9.14 | Phase III trial of casopitant, a novel neurokinin-1 receptor antagonist, for the prevention of nausea and vomiting in patients receiving moderately emetogenic chemotherapy. ( Apornwirat, W; Aziz, Z; Grunberg, SM; Guckert, M; Herrstedt, J; Levin, J; Ranganathan, S; Roila, F; Russo, MW; Shaharyar, A; Van Belle, S, 2009) |
| "Twenty-six children (ages 18 mo to 15 y) receiving intrathecal chemotherapy with either methotrexate or the combination of methotrexate, hydrocortisone, and Ara-C for the prophylactic treatment of central nervous system leukemia were randomly assigned to receive an infusion of normal saline or ondansetron at one of two doses (0." | 9.09 | Randomized, double-blind, crossover, placebo-controlled trial of intravenous ondansetron for the prevention of intrathecal chemotherapy-induced vomiting in children. ( Atlas, MP; Giugliano, DM; Mahan, RA; Parker, RI; Prakash, D, 2001) |
| "The effect of a single intravenous dose of ondansetron in preventing postoperative nausea and emesis (retching and vomiting) (PONV) was investigated in a randomized, double-blind, placebo-controlled, multicentre, international study." | 9.07 | A single i.v. dose of ondansetron 8 mg prior to induction of anaesthesia reduces postoperative nausea and vomiting in gynaecological patients. ( Abrahamsson, J; Briggs, L; Forrler, M; Hellstern, K; Helmers, JH; Moodley, J; Soni, J, 1993) |
| "The effect of three times daily oral ondansetron in preventing postoperative nausea and vomiting was investigated in two randomized, double-blind, placebo-controlled, multi-centre studies." | 9.07 | Oral ondansetron in the prevention of postoperative nausea and vomiting. ( Helmers, JH, 1992) |
| "The safety and efficacy of ondansetron were evaluated in the treatment of postoperative nausea and vomiting." | 9.07 | Ondansetron in the treatment of postoperative nausea and vomiting in ambulatory outpatients: a dose-comparative, stratified, multicentre study. ( Apfelbaum, J; Clayborn, L; Du Pen, S; Leslie, J; Mingus, M; Scuderi, P; Sharifi-Azad, S; Sung, YF; Talke, P; Wetchler, B, 1992) |
| "To assess the efficacy of ondansetron and the incidence of headache when used as prophylaxis for postoperative vomiting." | 8.80 | Ondansetron in the prophylaxis of postoperative vomiting: a meta-analysis. ( Canosa, LG; Figueredo, ED, 1998) |
| "The authors reviewed efficacy and safety data for ondansetron for preventing postoperative nausea and vomiting (PONV)." | 8.79 | Efficacy, dose-response, and safety of ondansetron in prevention of postoperative nausea and vomiting: a quantitative systematic review of randomized placebo-controlled trials. ( McQuay, HJ; Moore, RA; Reynolds, DJ; Tramèr, MR, 1997) |
| "Monosodium glutamate induces behaviors thought to reflect headache and nausea in rats." | 8.12 | Peripheral N-methyl-D-aspartate receptor activation contributes to monosodium glutamate-induced headache but not nausea behaviours in rats. ( Benbow, T; Cairns, BE; Exposto, FG; Sheikhi, A; Svensson, P; Teja, F, 2022) |
| "Fatigue is common in primary biliary cirrhosis (PBC)." | 6.71 | A randomized, controlled crossover trial of ondansetron in patients with primary biliary cirrhosis and fatigue. ( Burak, KW; Girlan, L; Heathcote, EJ; Heslegrave, RJ; Huet, PM; Swain, M; Theal, JJ; Tomlinson, GA; Toosi, MN, 2005) |
| "Postoperative nausea and vomiting are observed in increased frequency after laparoscopic surgery." | 6.70 | Tropisetron vs ondansetron for prevention of postoperative nausea and vomiting after laparoscopic cholecystectomy: a randomized double-blind, placebo-controlled study. ( Argiriadou, H; Georgiou, M; Papagiannopoulou, P; Papaziogas, B; Papaziogas, T; Parlapani, A; Pavlidis, T, 2002) |
| "001) linear dose-response relationship was observed over the entire dolasetron dosage range for all efficacy parameters." | 6.68 | Therapeutic equivalence of single oral doses of dolasetron mesilate and multiple doses of ondansetron for the prevention of emesis after moderately emetogenic chemotherapy. European Dolasetron Comparative Study Group. ( Chemaissani, A; Cognetti, F; Conte, PF; Cortes-Funes, H; Del Favero, A; Diaz-Rubio, E; Dressler, H; Duclos, B; Fauser, AA, 1996) |
| "The purpose of this phase III trial was to evaluate the efficacy and safety of regimens containing casopitant, a novel neurokinin-1 receptor antagonist, for the prevention of chemotherapy-induced nausea and vomiting during the first cycle in patients receiving moderately emetogenic chemotherapy (MEC)." | 5.14 | Phase III trial of casopitant, a novel neurokinin-1 receptor antagonist, for the prevention of nausea and vomiting in patients receiving moderately emetogenic chemotherapy. ( Apornwirat, W; Aziz, Z; Grunberg, SM; Guckert, M; Herrstedt, J; Levin, J; Ranganathan, S; Roila, F; Russo, MW; Shaharyar, A; Van Belle, S, 2009) |
| "Compared with ondansetron alone, the casopitant and ondansetron combination results in superior emesis prevention during the first 24 h postoperatively in female patients with known risk factors for postoperative nausea and vomiting." | 5.14 | Phase II study to evaluate the safety and efficacy of the oral neurokinin-1 receptor antagonist casopitant (GW679769) administered with ondansetron for the prevention of postoperative and postdischarge nausea and vomiting in high-risk patients. ( Blackburn, L; Chung, F; Johnson, B; Kutsogiannis, DJ; Lane, SR; Levin, J; Pergolizzi, JV; Singla, NK; Singla, SK, 2010) |
| "Twenty-six children (ages 18 mo to 15 y) receiving intrathecal chemotherapy with either methotrexate or the combination of methotrexate, hydrocortisone, and Ara-C for the prophylactic treatment of central nervous system leukemia were randomly assigned to receive an infusion of normal saline or ondansetron at one of two doses (0." | 5.09 | Randomized, double-blind, crossover, placebo-controlled trial of intravenous ondansetron for the prevention of intrathecal chemotherapy-induced vomiting in children. ( Atlas, MP; Giugliano, DM; Mahan, RA; Parker, RI; Prakash, D, 2001) |
| "A single IV dose of either 8, 24, or 32 mg of ondansetron combined with a single 20-mg IV dose of dexamethasone resulted in good control of acute emesis across a wide spectrum of chemotherapy regimens." | 5.08 | Adjusting the dose of intravenous ondansetron plus dexamethasone to the emetogenic potential of the chemotherapy regimen. ( Beck, T; Cohen, JR; Griffen, D; Hainsworth, JD; Harker, WG; Hesketh, PJ; Kessler, JF; Kris, MG; Lester, E; Uhlenhopp, M, 1995) |
| "More than 2000 patients at high risk of postoperative nausea and vomiting were given either placebo, ondansetron 4 mg, or droperidol 0." | 5.08 | A comparison of the efficacy, safety, and patient satisfaction of ondansetron versus droperidol as antiemetics for elective outpatient surgical procedures. S3A-409 and S3A-410 Study Groups. ( Creed, MR; Duncan, B; Fortney, JT; Gan, TJ; Glass, PS; Graczyk, S; Khalil, S; McKenzie, R; Melson, T; Moote, C; Parasuraman, TV; Parrillo, S; Wermeling, D; Wetchler, B, 1998) |
| "The effect of a single intravenous dose of ondansetron in preventing postoperative nausea and emesis (retching and vomiting) (PONV) was investigated in a randomized, double-blind, placebo-controlled, multicentre, international study." | 5.07 | A single i.v. dose of ondansetron 8 mg prior to induction of anaesthesia reduces postoperative nausea and vomiting in gynaecological patients. ( Abrahamsson, J; Briggs, L; Forrler, M; Hellstern, K; Helmers, JH; Moodley, J; Soni, J, 1993) |
| "The effect of three times daily oral ondansetron in preventing postoperative nausea and vomiting was investigated in two randomized, double-blind, placebo-controlled, multi-centre studies." | 5.07 | Oral ondansetron in the prevention of postoperative nausea and vomiting. ( Helmers, JH, 1992) |
| "The safety and efficacy of ondansetron were evaluated in the treatment of postoperative nausea and vomiting." | 5.07 | Ondansetron in the treatment of postoperative nausea and vomiting in ambulatory outpatients: a dose-comparative, stratified, multicentre study. ( Apfelbaum, J; Clayborn, L; Du Pen, S; Leslie, J; Mingus, M; Scuderi, P; Sharifi-Azad, S; Sung, YF; Talke, P; Wetchler, B, 1992) |
| "To assess the efficacy of ondansetron and the incidence of headache when used as prophylaxis for postoperative vomiting." | 4.80 | Ondansetron in the prophylaxis of postoperative vomiting: a meta-analysis. ( Canosa, LG; Figueredo, ED, 1998) |
| "The authors reviewed efficacy and safety data for ondansetron for preventing postoperative nausea and vomiting (PONV)." | 4.79 | Efficacy, dose-response, and safety of ondansetron in prevention of postoperative nausea and vomiting: a quantitative systematic review of randomized placebo-controlled trials. ( McQuay, HJ; Moore, RA; Reynolds, DJ; Tramèr, MR, 1997) |
| "Monosodium glutamate induces behaviors thought to reflect headache and nausea in rats." | 4.12 | Peripheral N-methyl-D-aspartate receptor activation contributes to monosodium glutamate-induced headache but not nausea behaviours in rats. ( Benbow, T; Cairns, BE; Exposto, FG; Sheikhi, A; Svensson, P; Teja, F, 2022) |
| "Fatigue is common in primary biliary cirrhosis (PBC)." | 2.71 | A randomized, controlled crossover trial of ondansetron in patients with primary biliary cirrhosis and fatigue. ( Burak, KW; Girlan, L; Heathcote, EJ; Heslegrave, RJ; Huet, PM; Swain, M; Theal, JJ; Tomlinson, GA; Toosi, MN, 2005) |
| "Postoperative nausea and vomiting are observed in increased frequency after laparoscopic surgery." | 2.70 | Tropisetron vs ondansetron for prevention of postoperative nausea and vomiting after laparoscopic cholecystectomy: a randomized double-blind, placebo-controlled study. ( Argiriadou, H; Georgiou, M; Papagiannopoulou, P; Papaziogas, B; Papaziogas, T; Parlapani, A; Pavlidis, T, 2002) |
| "Nausea was absent or mild in 79% of patients on day 1, 45% on day 2 and 41% on day 3." | 2.68 | A phase II study of ondansetron as antiemetic prophylaxis in patients receiving high-dose polychemotherapy and stem cell transplantation. ( Barbounis, V; Efremidis, AP; Hatzichristou, H; Koumakis, G; Tsousis, S; Vassilomanolakis, M, 1995) |
| "Headache was frequent in the control (69%), i." | 2.68 | The prophylactic antiemetic efficacy of prochlorperazine and ondansetron in nasal septal surgery: a randomized double-blind comparison. ( van den Berg, AA, 1996) |
| "001) linear dose-response relationship was observed over the entire dolasetron dosage range for all efficacy parameters." | 2.68 | Therapeutic equivalence of single oral doses of dolasetron mesilate and multiple doses of ondansetron for the prevention of emesis after moderately emetogenic chemotherapy. European Dolasetron Comparative Study Group. ( Chemaissani, A; Cognetti, F; Conte, PF; Cortes-Funes, H; Del Favero, A; Diaz-Rubio, E; Dressler, H; Duclos, B; Fauser, AA, 1996) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 14 (56.00) | 18.2507 |
| 2000's | 6 (24.00) | 29.6817 |
| 2010's | 3 (12.00) | 24.3611 |
| 2020's | 2 (8.00) | 2.80 |
| Authors | Studies |
|---|---|
| Benbow, T | 1 |
| Teja, F | 1 |
| Sheikhi, A | 1 |
| Exposto, FG | 1 |
| Svensson, P | 1 |
| Cairns, BE | 1 |
| Wang, EHZ | 1 |
| Sunderland, S | 1 |
| Edwards, NY | 1 |
| Chima, NS | 1 |
| Yarnold, CH | 1 |
| Schwarz, SKW | 1 |
| Coley, MA | 1 |
| Schoen, NB | 1 |
| Jermakowicz, WJ | 1 |
| Luca, CC | 1 |
| Jagid, JR | 1 |
| Herrstedt, J | 1 |
| Apornwirat, W | 1 |
| Shaharyar, A | 1 |
| Aziz, Z | 1 |
| Roila, F | 1 |
| Van Belle, S | 1 |
| Russo, MW | 1 |
| Levin, J | 2 |
| Ranganathan, S | 1 |
| Guckert, M | 1 |
| Grunberg, SM | 1 |
| Sharma, R | 1 |
| Panda, A | 1 |
| Singla, NK | 1 |
| Singla, SK | 1 |
| Chung, F | 1 |
| Kutsogiannis, DJ | 1 |
| Blackburn, L | 1 |
| Lane, SR | 1 |
| Johnson, B | 1 |
| Pergolizzi, JV | 1 |
| Argiriadou, H | 1 |
| Papaziogas, B | 1 |
| Pavlidis, T | 1 |
| Parlapani, A | 1 |
| Georgiou, M | 1 |
| Papagiannopoulou, P | 1 |
| Papaziogas, T | 1 |
| Theal, JJ | 1 |
| Toosi, MN | 1 |
| Girlan, L | 1 |
| Heslegrave, RJ | 1 |
| Huet, PM | 1 |
| Burak, KW | 1 |
| Swain, M | 1 |
| Tomlinson, GA | 1 |
| Heathcote, EJ | 1 |
| Wilkes, G | 1 |
| Hesketh, PJ | 1 |
| Beck, T | 1 |
| Uhlenhopp, M | 1 |
| Kris, MG | 1 |
| Hainsworth, JD | 1 |
| Harker, WG | 1 |
| Cohen, JR | 1 |
| Lester, E | 1 |
| Kessler, JF | 1 |
| Griffen, D | 1 |
| Veneziano, M | 1 |
| Framarino Dei Malatesta, M | 1 |
| Bandiera, AF | 1 |
| Fiorelli, C | 1 |
| Galati, M | 1 |
| Paolucci, A | 1 |
| Helmers, JH | 2 |
| Briggs, L | 1 |
| Abrahamsson, J | 1 |
| Soni, J | 1 |
| Moodley, J | 1 |
| Forrler, M | 1 |
| Hellstern, K | 1 |
| Barbounis, V | 1 |
| Koumakis, G | 1 |
| Vassilomanolakis, M | 1 |
| Hatzichristou, H | 1 |
| Tsousis, S | 1 |
| Efremidis, AP | 1 |
| van den Berg, AA | 1 |
| Fauser, AA | 1 |
| Duclos, B | 1 |
| Chemaissani, A | 1 |
| Del Favero, A | 1 |
| Cognetti, F | 1 |
| Diaz-Rubio, E | 1 |
| Cortes-Funes, H | 1 |
| Conte, PF | 1 |
| Dressler, H | 1 |
| Boike, SC | 1 |
| Ilson, B | 1 |
| Zariffa, N | 1 |
| Jorkasky, DK | 1 |
| Tramèr, MR | 1 |
| Reynolds, DJ | 1 |
| Moore, RA | 1 |
| McQuay, HJ | 1 |
| Fortney, JT | 1 |
| Gan, TJ | 1 |
| Graczyk, S | 1 |
| Wetchler, B | 2 |
| Melson, T | 1 |
| Khalil, S | 1 |
| McKenzie, R | 1 |
| Parrillo, S | 1 |
| Glass, PS | 1 |
| Moote, C | 1 |
| Wermeling, D | 1 |
| Parasuraman, TV | 1 |
| Duncan, B | 1 |
| Creed, MR | 1 |
| Figueredo, ED | 1 |
| Canosa, LG | 1 |
| Shuster, J | 1 |
| McCune, JS | 1 |
| Oertel, MD | 1 |
| Pfeifer, D | 1 |
| Houston, SA | 1 |
| Bingham, A | 1 |
| Sawyer, WT | 1 |
| Lindley, CM | 1 |
| Parker, RI | 1 |
| Prakash, D | 1 |
| Mahan, RA | 1 |
| Giugliano, DM | 1 |
| Atlas, MP | 1 |
| Du Pen, S | 1 |
| Scuderi, P | 1 |
| Sung, YF | 1 |
| Mingus, M | 1 |
| Clayborn, L | 1 |
| Leslie, J | 1 |
| Talke, P | 1 |
| Apfelbaum, J | 1 |
| Sharifi-Azad, S | 1 |
| Kidgell, AE | 1 |
| Butcher, ME | 1 |
| Brown, GW | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Double-blinded, Randomized Control Trial of Prophylactic Ondansetron in a Post-operative Cardiac Surgery Population for Post-operative Nausea and Vomiting[NCT02966041] | 186 participants (Actual) | Interventional | 2018-03-06 | Completed | |||
| Triple Combination of Fosaprepitant, Dexamethasone and Palonosetron Versus Combination of Dexamethasone and Palonosetron for the Prevention of Postoperative Nausea and Vomiting in Patients Undergoing Laparoscopic Gastrointestinal Surgery[NCT04853147] | Phase 3 | 1,154 participants (Actual) | Interventional | 2021-04-27 | Completed | ||
| A Phase III, Multicenter, Randomized, Double-Blind, Active Controlled, Parallel Group Study of the Safety and Efficacy of the Intravenous and Oral Formulations of the Neurokinin-1 Receptor Antagonist Casopitant (GW679769) in Combination With Ondansetron a[NCT00366834] | Phase 3 | 1,840 participants (Actual) | Interventional | 2006-07-31 | Completed | ||
| A Multicenter, Randomized, Double-blind, Placebo-controlled, Dose-ranging, Parallel Group Phase II Study to Evaluate the Safety, Efficacy and Pharmacokinetics of the Oral Neurokinin-1 Receptor Antagonist, GW679769, When Administered With Intravenous Ondan[NCT00108095] | Phase 2 | 701 participants (Actual) | Interventional | 2004-10-31 | Completed | ||
| Optimizing Anesthesia Antiemetic Measures Versus Combination With Dexamethasone or Ondansetron in the Prevention of Postoperative Nausea and Vomiting.[NCT00825071] | Phase 4 | 180 participants (Actual) | Interventional | 2007-11-30 | Completed | ||
| Comparison Between Ondansetron 8 mg and Lidocain 40 mg in Preventing Pain Due to Propofol Injection[NCT03134612] | Phase 2 | 104 participants (Actual) | Interventional | 2016-07-31 | Completed | ||
| A Prospective Evaluation of an Anesthesia Protocol to Reduce Post-operative and Post-discharge Nausea and Vomiting in a High Risk Orthognathic Surgery Population[NCT01592708] | 233 participants (Actual) | Interventional | 2012-06-30 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Anesthesia start time determined from anesthesia portion of the medical record. Time at which discharge order was placed will serve as time of discharge. (NCT01592708)
Timeframe: Anesthesia start time to placement of hospital discharge order - average 26 - 28 hours
| Intervention | hours (Median) |
|---|---|
| Intervention Cohort | 26.4 |
| Comparison Cohort | 28.2 |
To be assessed based on patient diary completed daily for 1 week following discharge to home from the hospital (NCT01592708)
Timeframe: 1 week from discharge from hospital
| Intervention | percentage of subjects with PDN (Number) |
|---|---|
| Intervention Cohort | 72 |
| Comparison Cohort | 60 |
(NCT01592708)
Timeframe: 1 week post discharge
| Intervention | percentage of subjects with PDV (Number) |
|---|---|
| Intervention Cohort | 22 |
| Comparison Cohort | 29 |
End of surgery time determined by anesthesia portion of the medical record. PONV to be assessed by review of surgeons' and nurses' notes in the medical record as well as through review of patient diaries. Vomiting constitutes a safety issue and, as such, associated adverse events will be noted. (NCT01592708)
Timeframe: End of surgery to discharge from hospital
| Intervention | percentage of subjects with PON (Number) |
|---|---|
| Intervention Cohort | 24 |
| Comparison Cohort | 70 |
(NCT01592708)
Timeframe: End of surgery to discharge from hospital
| Intervention | percentage of subjects with POV (Number) |
|---|---|
| Intervention Cohort | 11 |
| Comparison Cohort | 28 |
3 reviews available for ondansetron and Headache
| Article | Year |
|---|---|
Efficacy, dose-response, and safety of ondansetron in prevention of postoperative nausea and vomiting: a quantitative systematic review of randomized placebo-controlled trials.
Topics: Antiemetics; Dose-Response Relationship, Drug; Headache; Humans; Liver; Nausea; Ondansetron; Postope | 1997 |
Efficacy, dose-response, and safety of ondansetron in prevention of postoperative nausea and vomiting: a quantitative systematic review of randomized placebo-controlled trials.
Topics: Antiemetics; Dose-Response Relationship, Drug; Headache; Humans; Liver; Nausea; Ondansetron; Postope | 1997 |
Efficacy, dose-response, and safety of ondansetron in prevention of postoperative nausea and vomiting: a quantitative systematic review of randomized placebo-controlled trials.
Topics: Antiemetics; Dose-Response Relationship, Drug; Headache; Humans; Liver; Nausea; Ondansetron; Postope | 1997 |
Efficacy, dose-response, and safety of ondansetron in prevention of postoperative nausea and vomiting: a quantitative systematic review of randomized placebo-controlled trials.
Topics: Antiemetics; Dose-Response Relationship, Drug; Headache; Humans; Liver; Nausea; Ondansetron; Postope | 1997 |
Ondansetron in the prophylaxis of postoperative vomiting: a meta-analysis.
Topics: Administration, Oral; Adult; Antiemetics; Child; Female; Follow-Up Studies; Headache; Humans; Incide | 1998 |
Antiemetic control: 5-HT3 antagonists: review of clinical results, with particular emphasis on ondansetron.
Topics: Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Granisetron; Headache; Human | 1990 |
15 trials available for ondansetron and Headache
| Article | Year |
|---|---|
A Single Prophylactic Dose of Ondansetron Given at Cessation of Postoperative Propofol Sedation Decreases Postoperative Nausea and Vomiting in Cardiac Surgery Patients: A Randomized Controlled Trial.
Topics: Aged; Antiemetics; Arrhythmias, Cardiac; Cardiac Surgical Procedures; Cardiopulmonary Bypass; Double | 2020 |
A Single Prophylactic Dose of Ondansetron Given at Cessation of Postoperative Propofol Sedation Decreases Postoperative Nausea and Vomiting in Cardiac Surgery Patients: A Randomized Controlled Trial.
Topics: Aged; Antiemetics; Arrhythmias, Cardiac; Cardiac Surgical Procedures; Cardiopulmonary Bypass; Double | 2020 |
A Single Prophylactic Dose of Ondansetron Given at Cessation of Postoperative Propofol Sedation Decreases Postoperative Nausea and Vomiting in Cardiac Surgery Patients: A Randomized Controlled Trial.
Topics: Aged; Antiemetics; Arrhythmias, Cardiac; Cardiac Surgical Procedures; Cardiopulmonary Bypass; Double | 2020 |
A Single Prophylactic Dose of Ondansetron Given at Cessation of Postoperative Propofol Sedation Decreases Postoperative Nausea and Vomiting in Cardiac Surgery Patients: A Randomized Controlled Trial.
Topics: Aged; Antiemetics; Arrhythmias, Cardiac; Cardiac Surgical Procedures; Cardiopulmonary Bypass; Double | 2020 |
Phase III trial of casopitant, a novel neurokinin-1 receptor antagonist, for the prevention of nausea and vomiting in patients receiving moderately emetogenic chemotherapy.
Topics: Administration, Oral; Alopecia; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Brea | 2009 |
Phase II study to evaluate the safety and efficacy of the oral neurokinin-1 receptor antagonist casopitant (GW679769) administered with ondansetron for the prevention of postoperative and postdischarge nausea and vomiting in high-risk patients.
Topics: Administration, Oral; Adolescent; Adult; Anesthesia, General; Antiemetics; Cholecystectomy, Laparosc | 2010 |
Tropisetron vs ondansetron for prevention of postoperative nausea and vomiting after laparoscopic cholecystectomy: a randomized double-blind, placebo-controlled study.
Topics: Adult; Antiemetics; Cholecystectomy, Laparoscopic; Double-Blind Method; Female; Headache; Humans; In | 2002 |
A randomized, controlled crossover trial of ondansetron in patients with primary biliary cirrhosis and fatigue.
Topics: Constipation; Cross-Over Studies; Fatigue; Headache; Humans; Liver Cirrhosis, Biliary; Middle Aged; | 2005 |
Adjusting the dose of intravenous ondansetron plus dexamethasone to the emetogenic potential of the chemotherapy regimen.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Drug | 1995 |
A single i.v. dose of ondansetron 8 mg prior to induction of anaesthesia reduces postoperative nausea and vomiting in gynaecological patients.
Topics: Adolescent; Adult; Aged; Anesthesia, General; Bradycardia; Constipation; Double-Blind Method; Female | 1993 |
A phase II study of ondansetron as antiemetic prophylaxis in patients receiving high-dose polychemotherapy and stem cell transplantation.
Topics: Adolescent; Adult; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Constipation; Female | 1995 |
The prophylactic antiemetic efficacy of prochlorperazine and ondansetron in nasal septal surgery: a randomized double-blind comparison.
Topics: Adolescent; Adult; Anesthesia, General; Antiemetics; Blood Pressure; Child; Double-Blind Method; Fem | 1996 |
Therapeutic equivalence of single oral doses of dolasetron mesilate and multiple doses of ondansetron for the prevention of emesis after moderately emetogenic chemotherapy. European Dolasetron Comparative Study Group.
Topics: Adult; Aged; Analysis of Variance; Antiemetics; Antineoplastic Agents; Dose-Response Relationship, D | 1996 |
Cardiovascular effects of i.v. granisetron at two administration rates and of ondansetron in healthy adults.
Topics: Adult; Antiemetics; Double-Blind Method; Drug Interactions; Electrocardiography; Female; Granisetron | 1997 |
A comparison of the efficacy, safety, and patient satisfaction of ondansetron versus droperidol as antiemetics for elective outpatient surgical procedures. S3A-409 and S3A-410 Study Groups.
Topics: Adolescent; Adult; Aged; Ambulatory Surgical Procedures; Anesthesia, Intravenous; Anesthetics, Inhal | 1998 |
Randomized, double-blind, crossover, placebo-controlled trial of intravenous ondansetron for the prevention of intrathecal chemotherapy-induced vomiting in children.
Topics: Adolescent; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Cr | 2001 |
Oral ondansetron in the prevention of postoperative nausea and vomiting.
Topics: Administration, Oral; Adult; Alanine Transaminase; Aspartate Aminotransferases; Constipation; Double | 1992 |
Ondansetron in the treatment of postoperative nausea and vomiting in ambulatory outpatients: a dose-comparative, stratified, multicentre study.
Topics: Adolescent; Adult; Aged; Ambulatory Surgical Procedures; Child; Female; Headache; Humans; Injections | 1992 |
7 other studies available for ondansetron and Headache
| Article | Year |
|---|---|
Peripheral N-methyl-D-aspartate receptor activation contributes to monosodium glutamate-induced headache but not nausea behaviours in rats.
Topics: Amino Acids; Animals; Aspartic Acid; Female; Glutamic Acid; Headache; Kynurenic Acid; Male; Metoclop | 2022 |
Acute symptomatic peri-lead edema 33 hours after deep brain stimulation surgery: a case report.
Topics: Anti-Inflammatory Agents; Brain Edema; Deep Brain Stimulation; Dexamethasone; Headache; Humans; Male | 2017 |
Ondansetron-induced headache in a parturient mimicking postdural puncture headache.
Topics: Adult; Antiemetics; Cesarean Section; Diagnostic Errors; Female; Headache; Humans; Ondansetron; Post | 2010 |
Antiemetic agents.
Topics: Administration, Oral; Anorexia; Antiemetics; Antineoplastic Agents; Aprepitant; Asthenia; Constipati | 2007 |
Ondansetron-induced headache. Our experience in gynecological cancer.
Topics: Breast Neoplasms; Female; Genital Neoplasms, Female; Headache; Humans; Migraine Disorders; Ondansetr | 1995 |
Ondansetron and headache.
Topics: Antiemetics; Dizziness; Female; Fever; Headache; Humans; Middle Aged; Nursing Assessment; Ondansetro | 1999 |
Evaluation of outcomes in converting from intravenous ondansetron to oral granisetron: an observational study.
Topics: Administration, Oral; Adolescent; Adult; Antiemetics; Child; Constipation; Diarrhea; Drug Utilizatio | 2001 |